Skip to main content
SpringerLink
Log in

Posterior Reversible Encephalopathy Syndrome (PRES) in Cancer Patients

  • Living reference work entry
  • First Online:
Book cover Oncologic Critical Care

  • 255 Accesses

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a frequently dramatic clinical disorder characterized by a constellation of symptoms with imaging correlates. Typically, patients present with changes in mental status, visual disturbances, headaches, seizures, or focal neurological deficits. Imaging findings are classically in a posterior vascular distribution; however, PRES has been now recognized to involve other areas of the central nervous system. Once thought to be highly associated with systemic hypertension, PRES has been identified to be secondary to a growing list of conditions and therapies. With the introduction of newer oncological drugs and more frequent usage of magnetic resonance imaging, PRES has been increasingly identified in cancer patients. Rapid recognition and intervention is critical to preventing morbidity or mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Abughanimeh O, Abu Ghanimeh M, Qasrawi A, Al Momani LA, Madhusudhana S. Trastuzumab-associated posterior reversible encephalopathy syndrome. Cureus. 2018;10:e2686. https://doi.org/10.7759/cureus.2686.

    Article  PubMed  Google Scholar 

  2. Aruch DB, Renteria A. Simultaneous PRES and TMA secondary to tacrolimus after allogeneic bone marrow transplant. Blood. 2015;125:3963.

    Article  CAS  Google Scholar 

  3. Bakshi R, Bates VE, Mechtler LL, Kinkel PR, Kinkel WR. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. Epilepsia. 1998;39:295–9.

    Article  CAS  Google Scholar 

  4. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28:1320–7. https://doi.org/10.3174/ajnr.A0549.

    Article  CAS  PubMed  Google Scholar 

  5. Bartynski WS, Zeigler ZR, Shadduck RK, Lister J. Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation. Neurocrit Care. 2005;3:33–45. https://doi.org/10.1385/ncc:3:1:033.

    Article  CAS  PubMed  Google Scholar 

  6. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol. 2006;27:2179–90.

    CAS  PubMed  Google Scholar 

  7. Bhatt VR, et al. Central nervous system complications and outcomes after allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15:606–11. https://doi.org/10.1016/j.clml.2015.06.004.

    Article  PubMed  Google Scholar 

  8. Brady E, Parikh NS, Navi BB, Gupta A, Schweitzer AD. The imaging spectrum of posterior reversible encephalopathy syndrome: a pictorial review. Clin Imaging. 2018;47:80–9. https://doi.org/10.1016/j.clinimag.2017.08.008.

    Article  PubMed  Google Scholar 

  9. Burnett MM, Hess CP, Roberts JP, Bass NM, Douglas VC, Josephson SA. Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors. Clin Neurol Neurosurg. 2010;112:886–91. https://doi.org/10.1016/j.clineuro.2010.07.023.

    Article  PubMed  Google Scholar 

  10. Chen YH, Huang CH. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine. Clin Breast Cancer. 2012;12:222–5. https://doi.org/10.1016/j.clbc.2012.01.006.

    Article  PubMed  Google Scholar 

  11. Chen Z, Zhang G, Lerner A, Wang AH, Gao B, Liu J. Risk factors for poor outcome in posterior reversible encephalopathy syndrome: systematic review and meta-analysis. Quant Imaging Med Surg. 2018;8:421–32. https://doi.org/10.21037/qims.2018.05.07.

    Article  PubMed  Google Scholar 

  12. Chuk MK, et al. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: trial ADVL1211, a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2018;65:e27077. https://doi.org/10.1002/pbc.27077.

    Article  CAS  PubMed  Google Scholar 

  13. Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014;2014:952624. https://doi.org/10.1155/2014/952624.

    Article  PubMed  Google Scholar 

  14. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23:1038–48.

    PubMed  Google Scholar 

  15. Creutzig U, et al. First experience of the AML-Berlin-Frankfurt-Munster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer. 2017;64. https://doi.org/10.1002/pbc.26461.

  16. Crona DJ, Whang YE. Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. Investig New Drugs. 2015;33:751–4. https://doi.org/10.1007/s10637-014-0193-3.

    Article  Google Scholar 

  17. Datar S, Singh T, Rabinstein AA, Fugate JE, Hocker S. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome. Epilepsia. 2015a;56:564–8. https://doi.org/10.1111/epi.12933.

    Article  PubMed  Google Scholar 

  18. Datar S, Singh TD, Fugate JE, Mandrekar J, Rabinstein AA, Hocker S. Albuminocytologic dissociation in posterior reversible encephalopathy syndrome. Mayo Clin Proc. 2015b;90:1366–71. https://doi.org/10.1016/j.mayocp.2015.07.018.

    Article  CAS  PubMed  Google Scholar 

  19. Deguchi S, et al. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature. Investig New Drugs. 2018;36:346–9. https://doi.org/10.1007/s10637-017-0521-5.

    Article  Google Scholar 

  20. Donnelly J, Budohoski KP, Smielewski P, Czosnyka M. Regulation of the cerebral circulation: bedside assessment and clinical implications. Crit Care. 2016;20:129. https://doi.org/10.1186/s13054-016-1293-6.

    Article  PubMed  Google Scholar 

  21. Edvinsson L, Owman C, Sjoberg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res. 1976;115:377–93.

    Article  CAS  Google Scholar 

  22. Ferrara M, et al. Isolated pons involvement in posterior reversible encephalopathy syndrome: case report and review of the literature. eNeurologicalSci. 2017;6:51–4. https://doi.org/10.1016/j.ensci.2016.11.008.

    Article  PubMed  Google Scholar 

  23. Fitzgerald RT, et al. Elevation of serum lactate dehydrogenase at posterior reversible encephalopathy syndrome onset in chemotherapy-treated cancer patients. J Clin Neurosci. 2014;21:1575–8. https://doi.org/10.1016/j.jocn.2014.03.004.

    Article  CAS  PubMed  Google Scholar 

  24. Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD. Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) chemotherapy. Clin Lymphoma Myeloma Leuk. 2017;17:225–30. https://doi.org/10.1016/j.clml.2016.12.004.

    Article  PubMed  Google Scholar 

  25. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32. https://doi.org/10.4065/mcp.2009.0590.

    Article  PubMed  Google Scholar 

  26. Furubayashi N, Negishi T, Iwai H, Nagase K, Nakamura M. Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: a report of two cases. Mol Clin Oncol. 2017;7:281–4. https://doi.org/10.3892/mco.2017.1291.

    Article  PubMed  Google Scholar 

  27. Gao B, Liu FL, Zhao B. Association of degree and type of edema in posterior reversible encephalopathy syndrome with serum lactate dehydrogenase level: initial experience. Eur J Radiol. 2012;81:2844–7. https://doi.org/10.1016/j.ejrad.2011.12.010.

    Article  PubMed  Google Scholar 

  28. Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S. Clinical development of mTor inhibitors for renal cancer. Expert Opin Investig Drugs. 2017;26:1229–37. https://doi.org/10.1080/13543784.2017.1384813.

    Article  CAS  PubMed  Google Scholar 

  29. Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013;88:301–5. https://doi.org/10.1002/ajh.23402.

    Article  CAS  PubMed  Google Scholar 

  30. Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334: 494–500. https://doi.org/10.1056/nejm199602223340803.

    Article  CAS  PubMed  Google Scholar 

  31. How J, Blattner M, Fowler S, Wang-Gillam A, Schindler SE. Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist. 2016;21:112–7. https://doi.org/10.1097/nrl.0000000000000105.

    Article  PubMed  Google Scholar 

  32. Hualde Olascoaga J, Molins Castiella T, Souto Hernandez S, Becerril Moreno F, Yoldi Petri ME, Sagaseta de Ilurdoz M, Molina Garicano J. Reversible posterior leukoencephalopathy: report of two cases after vincristine treatment. Anales de pediatria. 2008;68:282–5. (Barcelona, Spain: 2003)

    Article  CAS  Google Scholar 

  33. Irvin W, MacDonald G, Smith JK, Kim WY. Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:2484–6. https://doi.org/10.1200/jco.2007.10.9991.

    Article  Google Scholar 

  34. Janjua TK, Hassan M, Afridi HK, Zahid NA. Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES). BMJ Case Rep. 2017;2017 https://doi.org/10.1136/bcr-2017-221571.

  35. Junewar V, et al. Neuroimaging features and predictors of outcome in eclamptic encephalopathy: a prospective observational study. AJNR Am J Neuroradiol. 2014;35:1728–34. https://doi.org/10.3174/ajnr.A3923.

    Article  CAS  PubMed  Google Scholar 

  36. Kamiya-Matsuoka C, Tummala S. Electrographic patterns in patients with posterior reversible encephalopathy syndrome and seizures. J Neurol Sci. 2017;375:294–8. https://doi.org/10.1016/j.jns.2017.02.017.

    Article  PubMed  Google Scholar 

  37. Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neuro-Oncol. 2016;128:75–84. https://doi.org/10.1007/s11060-016-2078-0.

    Article  Google Scholar 

  38. Karia SJ, Rykken JB, McKinney ZJ, Zhang L, McKinney AM. Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2016;37:415–22. https://doi.org/10.3174/ajnr.A4563.

    Article  CAS  PubMed  Google Scholar 

  39. Kastrup O, Schlamann M, Moenninghoff C, Forsting M, Goericke S. Posterior reversible encephalopathy syndrome: the spectrum of MR imaging patterns. Clin Neuroradiol. 2015;25:161–71. https://doi.org/10.1007/s00062-014-0293-7.

    Article  CAS  PubMed  Google Scholar 

  40. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology. 2007;69:894–7. https://doi.org/10.1212/01.wnl.0000269780.45472.16.

    Article  CAS  PubMed  Google Scholar 

  41. Kwon EJ, Kim SW, Kim KK, Seo HS, Kim DY. A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat. 2009;41:53–5. https://doi.org/10.4143/crt.2009.41.1.53.

    Article  PubMed  Google Scholar 

  42. LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. J Oncol Pharm Pract. 2017;23:71–4. https://doi.org/10.1177/1078155215620922.

    Article  PubMed  Google Scholar 

  43. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65:205–10. https://doi.org/10.1001/archneurol.2007.46.

    Article  PubMed  Google Scholar 

  44. Legriel S, et al. Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One. 2012;7:e44534. https://doi.org/10.1371/journal.pone.0044534.

    Article  CAS  PubMed  Google Scholar 

  45. Li X, Chai J, Wang Z, Lu L, Zhao Q, Zhou J, Ju F. Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review. Onco Targets Ther. 2018;11:4407–11. https://doi.org/10.2147/ott.S166605.

    Article  PubMed  Google Scholar 

  46. Liman TG, Bohner G, Heuschmann PU, Endres M, Siebert E. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol. 2012;259:155–64. https://doi.org/10.1007/s00415-011-6152-4.

    Article  CAS  PubMed  Google Scholar 

  47. Lv C, Gao B. Serum lactate dehydrogenase as a predictor of outcome in posterior reversible encephalopathy syndrome: imperative to unify. AJNR Am J Neuroradiol. 2015;36:E29–30. https://doi.org/10.3174/ajnr.A4243.

    Article  CAS  PubMed  Google Scholar 

  48. Makranz C, Khutsurauli S, Kalish Y, Eliahou R, Kadouri L, Gomori JM, Lossos A. Neurological variability in chemotherapy-induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: case reports and literature review. Mol Clin Oncol. 2018;8:178–82. https://doi.org/10.3892/mco.2017.1476.

    Article  PubMed  Google Scholar 

  49. Mancone S, Lycan T, Ahmed T, Topaloglu U, Dothard A, Petty WJ, Strowd RE. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol. 2018;265:1636. https://doi.org/10.1007/s00415-018-8890-z.

    Article  CAS  PubMed  Google Scholar 

  50. Marra A, Vargas M, Striano P, Del Guercio L, Buonanno P, Servillo G. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014;82:619–22. https://doi.org/10.1016/j.mehy.2014.02.022.

    Article  CAS  PubMed  Google Scholar 

  51. Massey J. Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU. J Clin Neurosci. 2017;40:57–9. https://doi.org/10.1016/j.jocn.2017.01.005.

    Article  PubMed  Google Scholar 

  52. Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:e76–8. https://doi.org/10.1200/jco.2011.38.7886.

    Article  CAS  Google Scholar 

  53. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, Teksam M. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007;189:904–12. https://doi.org/10.2214/ajr.07.2024.

    Article  PubMed  Google Scholar 

  54. Musiol K, Waz S, Boron M, Kwiatek M, Machnikowska-Sokolowska M, Gruszczynska K, Sobol-Milejska G. PRES in the course of hemato-oncological treatment in children. Childs Nerv Syst. 2018;34:691–9. https://doi.org/10.1007/s00381-017-3664-y.

    Article  PubMed  Google Scholar 

  55. Pandita A, Lehmann DF. Magnesium sulfate treatment correlates with improved neurological function in posterior reversible encephalopathy syndrome (PRES): report of a case. Neurologist. 2018;23:65–6. https://doi.org/10.1097/nrl.0000000000000174.

    Article  PubMed  Google Scholar 

  56. Parikh NS, et al. Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome. J Neurol Sci. 2017;380:11–5. https://doi.org/10.1016/j.jns.2017.06.044.

    Article  CAS  PubMed  Google Scholar 

  57. Rabinstein AA, Mandrekar J, Merrell R, Kozak OS, Durosaro O, Fugate JE. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis. 2012;21:254–8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.03.011.

    Article  PubMed  Google Scholar 

  58. Ract I, Poujade A, Carsin-Nicol B, Mouriaux F, Ferre JC. Spinal cord involvement in posterior reversible encephalopathy syndrome (PRES). J Neuroradiol. 2016;43:56–8. https://doi.org/10.1016/j.neurad.2015.09.004.

    Article  PubMed  Google Scholar 

  59. Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K, Tomoyasu S. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol. 2007;82:304–6. https://doi.org/10.1002/ajh.20772.

    Article  PubMed  Google Scholar 

  60. Schmidt V, Prell T, Treschl A, Klink A, Hochhaus A, Sayer HG. Clinical management of posterior reversible encephalopathy syndrome after allogeneic hematopoietic stem cell transplantation: a case series and review of the literature. Acta Haematol. 2016;135:1–10. https://doi.org/10.1159/000430489.

    Article  CAS  PubMed  Google Scholar 

  61. Schwartz R, Mulkern R, Vajapeyam S, Kacher DF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2009;30:E19; author reply E20. https://doi.org/10.3174/ajnr.A1285.

    Article  CAS  PubMed  Google Scholar 

  62. Schweitzer AD, et al. Imaging characteristics associated with clinical outcomes in posterior reversible encephalopathy syndrome. Neuroradiology. 2017;59:379–86. https://doi.org/10.1007/s00234-017-1815-1.

    Article  PubMed  Google Scholar 

  63. Seol YM, Kim DY, Kim HJ, Choi YJ. Reversible posterior leukoencephalopathy syndrome after Eribulin mesylate chemotherapy for breast cancer. Breast J. 2017;23:487–8. https://doi.org/10.1111/tbj.12776.

    Article  PubMed  Google Scholar 

  64. Siegal D, et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007;13:1369–79. https://doi.org/10.1016/j.bbmt.2007.07.013.

    Article  PubMed  Google Scholar 

  65. Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist. 2015;20:806–11. https://doi.org/10.1634/theoncologist.2014-0149.

    Article  PubMed  Google Scholar 

  66. Smets GJ, Loyson T, Van Paesschen W, Demaerel P, Nackaerts K. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review. Acta Clin Belg. 2017;1–7. https://doi.org/10.1080/17843286.2017.1403103.

  67. Tlemsani C, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011;6:253–8. https://doi.org/10.1007/s11523-011-0201-x.

    Article  PubMed  Google Scholar 

  68. Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol. 2007;18:608–9. https://doi.org/10.1093/annonc/mdl436.

    Article  CAS  PubMed  Google Scholar 

  69. Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127–248. https://doi.org/10.1016/j.jacc.2017.11.006.

    Article  PubMed  Google Scholar 

  70. Win MA, Thein KZ, Yeung SJ. Cancer immunotherapy-induced posterior reversible encephalopathy syndrome in an ED. Am J Emerg Med. 2017;35:663.e661–2. https://doi.org/10.1016/j.ajem.2016.10.069.

    Article  Google Scholar 

  71. Zhang L, Xu J. Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review. Am J Clin Exp Immunol. 2018;7:1–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

    Bryan Bonder

  2. Stem Cell Transplant Program, Seidman Cancer Center, University Hospitals Cleveland Medical Center, and Case Western Reserve University, Cleveland, OH, USA

    Marcos de Lima

Authors
  1. Bryan Bonder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcos de Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcos de Lima .

Editor information

Editors and Affiliations

  1. Department of Critical Care, University of Texas MD Anderson Cancer C Department of Critical Care, Houston, TX, USA

    Joseph L. Nates

  2. Department of Critical Care, University of Texas MD Anderson Cancer C Department of Critical Care, Houston, TX, USA

    Kristen J. Price

Section Editor information

  1. Critical Care Department, Universidad del Rosario Hospital Universitario Fundacion Santa Fe de, Bogota, Colombia, Colombia

    Yenny Cardenas

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Bonder, B., de Lima, M. (2019). Posterior Reversible Encephalopathy Syndrome (PRES) in Cancer Patients. In: Nates, J., Price, K. (eds) Oncologic Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-74698-2_37-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74698-2_37-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74698-2

  • Online ISBN: 978-3-319-74698-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation